arrow_back Civic Audit
Share share

Drug Supply Security: Facilitating Pharmaceutical Trade and Production

This act aims to enhance the security of drug supplies, especially during emergencies, by facilitating international trade and pharmaceutical production. Citizens can expect greater availability of medicines and more stable prices due to streamlined regulatory processes and international cooperation. These changes are intended to reduce the risk of drug shortages in the market.
Key points
Easier Drug Trade: Reducing or eliminating tariffs and regulatory barriers on drug imports, especially in emergencies.
Support for Drug Production: Promoting faster approval of manufacturing facilities and processes, and encouraging investment in pharmaceutical production.
Increased Transparency and Cooperation: Information sharing among countries to prevent supply chain issues and coordinate actions in the pharmaceutical sector.
Extension of Trade Agreement Authority: The U.S. government gains more time to negotiate new trade agreements, which may impact future drug import and export conditions.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_4711
Sponsor: Rep. Joyce, John [R-PA-13]
Process start date: 2021-07-27
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

International Pharmaceutical Supply Chain Security Agreement Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4711.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-27.

What are the main provisions?

Key points include:

  • Easier Drug Trade: Reducing or eliminating tariffs and regulatory barriers on drug imports, especially in emergencies.
  • Support for Drug Production: Promoting faster approval of manufacturing facilities and processes, and encouraging investment in pharmaceutical production.
  • Increased Transparency and Cooperation: Information sharing among countries to prevent supply chain issues and coordinate actions in the pharmaceutical sector.
  • Extension of Trade Agreement Authority: The U.S. government gains more time to negotiate new trade agreements, which may impact future drug import and export conditions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Joyce, John [R-PA-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy